Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-014920
Filing Date
2023-05-02
Accepted
2023-05-02 17:11:51
Documents
89
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aqst-20230331.htm   iXBRL 10-Q 1191177
2 EX-31.1 aqst-03312023ex311.htm EX-31.1 10986
3 EX-31.2 aqst-03312023ex312.htm EX-31.2 11202
4 EX-32.1 aqst-03312023ex321.htm EX-32.1 6482
5 EX-32.2 aqst-03312023ex322.htm EX-32.2 6548
  Complete submission text file 0001628280-23-014920.txt   6528109

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20230331.xsd EX-101.SCH 60450
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT aqst-20230331_cal.xml EX-101.CAL 61958
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT aqst-20230331_def.xml EX-101.DEF 255459
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20230331_lab.xml EX-101.LAB 599985
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20230331_pre.xml EX-101.PRE 416892
83 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20230331_htm.xml XML 925555
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38599 | Film No.: 23880380
SIC: 2834 Pharmaceutical Preparations